Sublingual Use of Atropine in Controlling Drooling in children with Cerebral Palsy sublingual atropine , cerebral palsay , drooling
Conditions
Interventions
Intervention:
Baseline assessment:
Before initiating the treatment, baseline measurements of drooling will be done by applying Drooling Impact Scale (DIS) for all patents meeting the inclusion criteri
Experimental Drug,Placebo Comparator Drug
SUBLINGUAL ATROPINE ADMINISTRATION,SUBLINGUAL NORMAL SALINE
Sponsors
THE CHILDERN HOSPITAL LAHORE
Eligibility
Sex/Gender
All
Age
4 Years to 15 Years
Inclusion criteria
Inclusion criteria: 1) Age 4 -15 years 2) All patient with Cerebral palsy with excessive Drooling According to Operational definition 3) Previously not used any medication or any therapy for drooling 4) Weight more than 10 kg 5)Electrocardiogram normal
Exclusion criteria
Exclusion criteria: 1)Patients with contraindications to atropine. 2)Individuals currently using medications that could interfere with atropine's effects will be excluded to ensure consistent results.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| efficacy of sublingual atropine in reducing drooling in children with cerebral palsy. BASE LINE ASSESMENT AND AFTER 7 DAYS AT THE END OF INTERVENTION DROOLING IMPACT SCALE (QUALITATIVE) | — |
Secondary
| Measure | Time frame |
|---|---|
| Quality of life , at the end of 7 days of intervention DROOLING IMPACT SCALE ,Safety and tolerability BASE LINE AND AT THE END OF 7 DAYS OF INTERVENTION MONITORING OF SDIE EFECT ,Effects on feeding and swallowing BASE LINE AND 7 DAYS AFTER INTERVENTION DROOLING IMPACT SCALE | — |
Countries
Pakistan
Contacts
Public ContactMUAAZ NAEEM
FELLOW DEVELOPMENTAL AND BEHAVIORAL PEDIATRICS CHILDERN HOSPITAL LAHORE
Outcome results
None listed